NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients with Sickle Cell Disease (SCD)

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

000844-H

Sponsoring Institute

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 100 Years

Referral Letter Required

No

Population Exclusion(s)

Children

Keywords

Hemodynamic;
Six-Minute Walk Test

Recruitment Keyword(s)

None

Condition(s)

SCD

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Diagnostic Test: Non-Invasive Infrared Spectroscopy

Supporting Site

National Heart, Lung, and Blood Institute

Sickle cell disease (SCD) is an inherited disorder of the blood. SCD can injure the smallest blood vessels, which can cause pain and damage organs all over the body. Some treatments are available, but researchers need better ways to monitor the effects of these treatments. An imaging technique called near infrared spectroscopy (NIRS) may be helpful.

Objective:

To test NIRS as a tool for measuring oxygen levels, blood flow, and the makeup of skin and muscle in patients with SCD.

Eligibility:

People aged 18 years and older with SCD. Healthy volunteers are also needed as a comparison for the changes in SCD patients.

Design:

Participants will be screened. They will have a physical exam, and 1 teaspoon of blood will be drawn.

Participants will have NIRS testing on their second visit. Probes will be placed on their skin. A blood pressure cuff will be placed on their arm. The cuff will be filled with air for up to 5 minutes and then released. Participants may be asked to breathe at a certain rate or hold their breath during these measurements.

At this visit, participants will also have an ultrasound exam to get images of their heart. They will be monitored while they walk for 6 minutes. They will have 1 tablespoon of blood drawn. Their height, weight, and vital signs will be measured.

Participants may be asked to return for up to 4 additional visits for NIRS testing within 120 days, but this is optional. The visits must be at least 3 days apart. Each visit will last up to an hour.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Sickle Cell Disease

-Individuals with confirmed sickle cell disease (HbSS and S beta 0 genotypes)

-18 years of age and older

-Willingness and capacity to provide informed consent

-Individuals must be on stable does of Hydroxyurea for 90 days prior to baseline visit

Ethnically matched controls

-Individuals with HbAA genotype

-18 years of age and older

-Willingness and capacity to provide informed consent

EXCLUSION CRITERIA:

Sickle Cell Disease

-Pain crisis requiring parenteral treatment within 4 weeks of screening/enrollment

-Blood transfusion within 60 days or exchange transfusion within 90 days of screening/enrollment

-Use of Oxbryta (voxelotor), Adakveo (crizanlizumab), and/or Endari (L-glutamine) within the 12 weeks prior to signing consent

-Women who are currently pregnant

-Presence of an arterial-venous shunt, recent axillary node dissection, or any deformity or surgical history that interferes with proper access for brachial cuff occlusion procedure of the extremities

-Mobility difficulties causing the inability to complete 6-minute walk test

Ethnically matched controls

-Women who are currently pregnant

-Presence of an arterial-venous shunt, recent axillary node dissection, or any deformity or surgical history that interferes with proper access for brachial cuff occlusion procedure of the extremities

-Mobility difficulties causing the inability to complete 6-minute walk test

-Blood transfusion within 60 days or exchange transfusion within 90 days of screening/enrollment


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Swee Lay Thein, M.D.
National Heart, Lung and Blood Institute (NHLBI)
NIHBC 10 - CLINICAL CENTER BG RM 6S241A
10 CENTER DR
BETHESDA MD 20892
(301) 435-2345
sweelay.thein@nih.gov

Dianna Lovins
National Heart, Lung and Blood Institute (NHLBI)
National Institutes of Health
Building 10
Room 3-2473
10 Center Drive
Bethesda, Maryland 20892
(301) 480-3765
dianna.lovins@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1
ccopr@nih.gov

Clinical Trials Number:

NCT05604547

--Back to Top--